Metabolic Disease News and Research

RSS

Obesity may be under diagnosed using BMI scale

We have relied on body mass index (BMI), a ratio of height to weight, to categorize people as overweight and obese for decades. A new study, however, suggests the use of BMI may be leading us to underestimate the obesity rate.

4 Apr 2012

High fat diets cause damage to blood vessels earlier than previously thought

High fat diets cause damage to blood vessels earlier than previously thought, and these structural and mechanical changes may be the first step in the development of high blood pressure.

4 Apr 2012

Ember adds Joslin's BMP7 technology to brown fat intellectual property portfolio

Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced the completion of an agreement with the Joslin Diabetes Center to exclusively license intellectual property covering bone morphogenetic protein 7 (BMP7), which has been shown to play a role in the regulation of brown fat development.

29 Mar 2012

Ember, Joslin aims to utilize brown fat for treatment of obesity and diabetes

Joslin Diabetes Center and Ember Therapeutics, Inc. today announced an agreement aimed at utilizing "brown fat," a type of fat that helps increase energy expenditure within the body, as a novel technique for managing obesity and diabetes. Joslin's Chief Academic Officer, Dr. Ronald Kahn and other Joslin faculty, Drs. Yu-Hua Tseng and Aaron Cypess, have performed pioneering work in this field over the past several years, and were the first to show that a natural protein called BMP7 can help modulate the levels of brown fat.

29 Mar 2012

Bariatric surgery better than standard medical treatment for severe type 2 diabetes

In the first published study of its kind, researchers from the Catholic University/Policlinico Gemelli in Rome, Italy, and NewYork-Presbyterian/Weill Cornell Medical Center found that bariatric surgery dramatically outperforms standard medical treatment of severe type 2 diabetes.

27 Mar 2012

Theracurmin shows positive impact on human diastolic functions

The research group led by Dr. Koji Hasegawa, Director of the Translational Research Division at the National Hospital Organization Kyoto Medical Center and Dr. Tatsuya Morimoto, Professor at the Molecular Medicine School of Pharmaceutical Sciences, University of Shizuoka, announced today based on the recent human clinical trials, that Theracurmin has continuously shown positive impact on human diastolic functions.

26 Mar 2012

Promising results from Esperion ETC-1002 Phase 2 clinical trial for dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced positive results from a Phase 2 clinical trial for ETC-1002.

26 Mar 2012

Soy-based S-equol lowers HbA1c, LDL cholesterol and improves vascular stiffness

A 12-week treatment of the fermented soy germ-based nutritional supplement containing S-equol significantly lowered hemoglobin A1c (HbA1c), LDL cholesterol and improved vascular stiffness, all factors that occur as part of metabolic syndrome, according to a first-of-its-kind peer-reviewed study reported in a poster at the Women's Health 2012 annual meeting.

19 Mar 2012

Conference highlights studies on metabolism, aging and monarch butterfly migration

The Genetics Society of America's 53rd Annual Drosophila Research Conference, March 7-11 at the Sheraton Chicago Hotel & Towers, will showcase diverse efforts to understand basic biological processes through the easy-to-study fruit fly, Drosophila melanogaster, and other insects.

12 Mar 2012

Nitrogen balance occurs with a precise 24-hour rhythm in mammals

Researchers at Case Western Reserve University School of Medicine demonstrated that nitrogen balance, the process of utilizing amino acids and disposing of their toxic byproducts, occurs with a precise 24-hour rhythm - also known as circadian rhythm - in mammals. Disruption of this cycle has a direct impact on survival of organisms, and may predispose one to life altering diseases including diabetes and cardiovascular disease.

7 Mar 2012

Unstructured free play, recess need to be reinstated in schools

Evaluating the Let's Move! Initiative, Dr. Melinda Sothern, Professor of Public Health and Jim Finks Chair of Health Promotion at LSU Health Sciences Center New Orleans, calls First Lady Michelle Obama brave for taking on the challenge of childhood obesity and suggests that she now consider working to move it up to the policy level.

14 Feb 2012

Negative consequences of maternal obesity can be reversed through exercise

Exercise is the key to overcoming the adverse metabolic effects passed on to offspring by their overweight mothers, with research showing for the first time these effects can be almost completely reversed through physical activity.

10 Feb 2012

Study identifies new gene variants linked with risk of T2D

The largest genetics study to date of type 2 diabetes (T2D) has identified new gene variants associated with risk for the common metabolic disease. An international scientific consortium, studying multiethnic populations, uncovered genes that may point to biological targets for developing more effective drugs for T2D.

10 Feb 2012

Whole-exome sequencing discovers cause of glycosylation disorders

Sequencing a patient's entire genome to discover the source of his or her disease is not routine - yet. But geneticists are getting close. A case report, published this week in the American Journal of Human Genetics, shows how researchers can combine a simple blood test with an "executive summary" scan of the genome to diagnose a type of severe metabolic disease.

4 Feb 2012

Researchers reveal how antipsychotics affect metabolism by SMAD3 activation

In a paper published January 31 in the journal Molecular Psychiatry, researchers at Sanford-Burnham Medical Research Institute (Sanford-Burnham) reveal how antipsychotic drugs interfere with normal metabolism by activating a protein called SMAD3, an important part of the transforming growth factor beta (TGFbeta) pathway.

2 Feb 2012

MT2 gene mutations may increase risk of diabetes

Researchers in Lille and Paris demonstrated that mutations in the melatonin receptor gene (melatonin or the "hormone of darkness" induces sleep) lead to an almost sevenfold increase in the risk of developing diabetes.

31 Jan 2012

KineMed, Pfizer enter research collaboration on metabolic diseases

KineMed, Inc. today announced a non-exclusive research collaboration with Pfizer Inc. for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes.

30 Jan 2012

Everist Genomics' CardioDefender Device to be featured at Wearable Technologies Conference

Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.

30 Jan 2012

Pediatric research project to expand data collection linked to newborn screening results

Within the first days of life, screening tests are performed on all newborns born in the U.S. to identify rare and often life-threatening medical conditions that are not apparent at birth. These newborn screening programs have been operating for decades, permitting doctors to intervene early and improve outcomes in potentially devastating conditions.

18 Jan 2012